AstraZeneca Q1 2025: Performance Catalysts Explode, $1.8 Billion in Revenue from China Market

On April 29, AstraZeneca announced its Q1 2025 financial report, with total quarterly revenue of $13.588 billion (+10%), of which product revenue was $12.875 billion (+9%), driven primarily by double-digit growth in oncology and biopharmaceuticals.

By regional distribution, Q1 2025 revenue from the U.S. market was $5.646 billion (+10%), while revenue from China was $1.805 billion (+5%), accounting for 13% of AstraZeneca's global market share.

In oncology, the best-selling Tagrisso (Osimertinib) achieved a quarterly sales revenue of $1.679 billion (+8%); Imfinzi (Durvalumab), Lynparza (Olaparib), Calquence (Acalbrutinib), and Enhertu (Trastuzumab deruxtecan) also saw growth; with the addition of regions handled by Taiho Pharmaceutical, Enhertu's global sales for Q1 2025 were $1.086 billion.

Among new products launched in the past two years, the globally first-in-class AKT inhibitor Truqap (Capivasertib) showed strong growth, with Q1 2025 sales reaching $132 million; AstraZeneca’s second ADC product, Datroway (Daratumumab), is still in its early stages, with Q1 2025 sales of $4 million.

At the time of the earnings release, AstraZeneca also announced the termination of the Phase III CAPItello-280 study, which aimed to evaluate Truqap (Capivasertib) in combination with docetaxel and androgen deprivation therapy (ADT), comparing it to docetaxel and ADT combined with a placebo in metastatic castration-resistant prostate cancer (mCRPC) patients.

The CAPItello-280 study was a global, randomized, double-blind Phase III trial involving 1,033 mCRPC patients whose disease continued to progress despite ADT treatment. The primary endpoints were radiographic progression-free survival (rPFS) and overall survival (OS) as assessed by investigators.

AstraZeneca stated that the decision to terminate the CAPItello-280 study was based on the recommendation of the Independent Data Monitoring Committee (IDMC), which concluded after reviewing the pre-specified interim analysis data that the combination of Truqap was unlikely to meet the dual primary endpoints of rPFS and OS at the end of the study. Truqap’s safety profile was consistent with previous studies.

In the CVRM (Cardiovascular, Renal, and Metabolic) field, the cornerstone product Farxiga (Dapagliflozin) continued to perform well, with Q1 2025 revenue of $2.058 billion (+16%). In the Respiratory and Immunology (R&I) field, the asthma drug Tezspire (Tezepelumab) showed impressive growth, with Q1 2025 revenue of $217 million (+85%).

AstraZeneca CEO Pascal Soriot said during the earnings release: “Our strong growth momentum has continued into 2025, and we are now entering an unprecedented period rich in catalysts. This year, we have already announced five positive Phase III study results, including the highly anticipated DESTINYBreast09 study of Enhertu, as well as the SERENA-6 study of camizestrant and the MATTERHORN study of Imfinzi; the latter two studies will be presented at the 2025 ASCO Annual Meeting, highlighting the significance of these data in the oncology field.

Our company is firmly committed to investing and developing in the U.S., and we will continue to benefit from our broad range of revenue sources and global production footprint, including 11 manufacturing sites in the U.S. covering small molecules, biologics, and cell therapies. In addition, we plan to further invest in U.S. production and R&D, leveraging two large R&D centers located in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, we are making progress towards our ambitious goal of achieving $80 billion in total revenue by 2030.”